NCT04595513View on ClinicalTrials.gov

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Tuberous Sclerosis ComplexEpilepsy
Interventions
DRUG

TAVT-18 (sirolimus)

The investigational drug product to be used in this study is TAVT-18, a proprietary formulation of sirolimus in clinical development, by Tavanta Therapeutics, Inc. It is provided in a powder formulation in pre-measured vials.

Trial Locations (1)

45229

Cincinnati Children's Hospital, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants | Biotech Hunter | Biotech Hunter